These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 8700005)

  • 1. [The effect of the dispersity of tegalid on its bioavailability].
    Lopatina NB; Lebedeva MN; Mikhaĭlitsyn FS; Khalikov SS
    Med Parazitol (Mosk); 1996; (1):23-5. PubMed ID: 8700005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tegalid distribution in the body of rats].
    Lopatina NB; Rodionov AP; Lebedeva MN; Mikhaĭlitsyn FS
    Med Parazitol (Mosk); 1993; (4):45-7. PubMed ID: 7968811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative biopharmaceutical study of tegalide].
    Lopatina NB; Lebedeva MN
    Med Parazitol (Mosk); 2000; (1):27-9. PubMed ID: 10808715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of luxabendazole after oral and intravenous administration to sheep.
    Ortiz AI; Alvarez-Bujidos L; Ferre I; Ordóñez D
    Am J Vet Res; 1997 Nov; 58(11):1263-6. PubMed ID: 9361890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of solubilization on the oral bioavailability of three benzimidazole carbamate drugs.
    Daniel-Mwambete K; Torrado S; Cuesta-Bandera C; Ponce-Gordo F; Torrado JJ
    Int J Pharm; 2004 Mar; 272(1-2):29-36. PubMed ID: 15019066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base.
    Hecq J; Deleers M; Fanara D; Vranckx H; Boulanger P; Le Lamer S; Amighi K
    Eur J Pharm Biopharm; 2006 Nov; 64(3):360-8. PubMed ID: 16846725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and relative bioavailability of praziquantel in healthy water buffalo after oral and intramuscular administration.
    Sun Y; Bu SJ
    J Vet Pharmacol Ther; 2012 Dec; 35(6):618-22. PubMed ID: 22239339
    [No Abstract]   [Full Text] [Related]  

  • 8. [A method for determining tegalid in biological material].
    Lopatina NB; Rodionov AP; Lebedeva MN; Mikhaĭlitsyn FS
    Med Parazitol (Mosk); 1993; (3):41-3. PubMed ID: 8041319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative plasma disposition of fenbendazole, oxfendazole and albendazole in dogs.
    Gokbulut C; Bilgili A; Hanedan B; McKellar QA
    Vet Parasitol; 2007 Sep; 148(3-4):279-87. PubMed ID: 17673370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of absolute oral bioavailability of moxidectin in dogs using a semi-simultaneous method: influence of lipid co-administration.
    Lallemand E; Lespine A; Alvinerie M; Bousquet-Melou A; Toutain PL
    J Vet Pharmacol Ther; 2007 Oct; 30(5):375-80. PubMed ID: 17803727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma disposition, faecal excretion and in vitro metabolism of oxibendazole following oral administration in horses.
    Gokbulut C; Nolan AM; McKellar QA
    Res Vet Sci; 2002 Feb; 72(1):11-5. PubMed ID: 12002632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipidic matrix of albendazole: an alternative for systemic infections.
    Savio E; Domínguez L; Malanga A; Quevedo D; Saldaña J; Camarote C; Ochoa A; Fagiolino P
    Boll Chim Farm; 1998 Oct; 137(9):345-9. PubMed ID: 9859596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A comparative study of befol pharmacokinetics in experimental animals and man].
    Rodionov AP; Ignatova NA; Kushnarev VV; Muzychenko AP
    Farmakol Toksikol; 1990; 53(2):62-3. PubMed ID: 2369959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of oral moxidectin bioavailability in rabbits by lipid co-administration.
    Bassissi MF; Lespine A; Alvinerie M
    Parasitol Res; 2004 Oct; 94(3):188-92. PubMed ID: 15338286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex-related plasma disposition of ivermectin following pour-on administration in goats.
    Gokbulut C; Bilgili A; Hanedan B; Aksit D; Aksoy AM; Turgut C
    Vet Parasitol; 2009 Jun; 162(3-4):342-5. PubMed ID: 19342177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of dose increase or cimetidine co-administration on albendazole bioavailability.
    Schipper HG; Koopmans RP; Nagy J; Butter JJ; Kager PA; Van Boxtel CJ
    Am J Trop Med Hyg; 2000; 63(5-6):270-3. PubMed ID: 11421376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New perspectives in bio-analytical techniques for preclinical characterization of a drug candidate: UPLC-MS/MS in in vitro metabolism and pharmacokinetic studies.
    Pedraglio S; Rozio MG; Misiano P; Reali V; Dondio G; Bigogno C
    J Pharm Biomed Anal; 2007 Jul; 44(3):665-73. PubMed ID: 17236736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of albendazole sulfoxide enantiomers administered in racemic form and separately in rats.
    Capece BP; Castells G; Godoy C; Arboix M; Cristòfol C
    Vet J; 2008 Aug; 177(2):297-9. PubMed ID: 17566773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of moxidectin after oral and subcutaneous administration to sheep.
    Alvinerie M; Escudero E; Sutra JF; Eeckhoutte C; Galtier P
    Vet Res; 1998; 29(2):113-8. PubMed ID: 9601143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics assessment of moxidectin long-acting formulation in cattle.
    Dupuy J; Sutra JF; Alvinerie M
    Vet Parasitol; 2007 Jul; 147(3-4):252-7. PubMed ID: 17543457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.